Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

toripalimab

Drug and asset intelligence for toripalimab with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 1
Stage: Development stage unavailable

Sponsor company

Shanghai Junshi Bioscience Co., Ltd. →

Recent signals(2)

StrategyAugust 20, 2026

Cost-effectiveness of Disitamab Vedotin Plus Toripalimab in HER2-Expressing Urothelial Cancer

The RC48-C016 trial conducted in China demonstrated that disitamab vedotin combined with toripalimab (DV+Torip) significantly improved overall survival and progression-free survival compared to traditional chemotherapy in patients with HER2-expressing advanced urothelial cancer.

ClinicalJuly 7, 2026

Phase III Trial of Toripalimab and Lenvatinib for Advanced HCC Initiated

A Phase III study has been initiated to evaluate Toripalimab combined with Lenvatinib versus placebo in advanced HCC.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts

(1)

Topline Data

Shanghai Junshi Bioscience Co., Ltd. — Toripalimab

July 7, 2026 · N/A

Indications

HER2-Expressing Advanced Urothelial Cancer →

Therapeutic areas

HER2-Expressing Advanced Urothelial Cancer →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.